---
document_datetime: 2025-12-02 04:50:21
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/veoza.html
document_name: veoza.html
version: success
processing_time: 0.1104406
conversion_datetime: 2025-12-25 07:59:30.106366
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Veoza

[RSS](/en/individual-human-medicine.xml/77412)

##### Authorised

This medicine is authorised for use in the European Union

fezolinetant Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Veoza](#news-on)
- [More information on Veoza](#related-medicines)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Veoza is a medicine used to treat moderate to severe vasomotor symptoms (also referred to as hot flushes or night sweats) associated with menopause.

Veoza contains the active substance fezolinetant.

Expand section

Collapse section

## How is Veoza used?

Veoza is available as tablets to be taken by mouth once a day. The medicine can only be obtained with a prescription.

For more information about using Veoza, see the package leaflet or contact your doctor or pharmacist.

## How does Veoza work?

Before menopause, there is a balance between oestrogen hormones and a protein called neurokinin B which regulates the brain's temperature control centre. As the body goes through menopause, oestrogen levels decline and this balance is disrupted, which can lead to vasomotor symptoms.

The active substance in Veoza, fezolinetant, blocks neurokinin B from attaching to its targets in the brain, thereby reducing the number and intensity of hot flushes and night sweats.

## What benefits of Veoza have been shown in studies?

Two main studies involving over 1,000 women showed that Veoza is effective at reducing the number and severity of hot flushes associated with menopause. After 4 weeks of treatment, the number of moderate to severe daily hot flushes was reduced on average by 53% in women taking Veoza 45 mg, compared with a reduction of 32% in women given placebo (a dummy treatment). After 12 weeks of treatment, the average reduction was 63% for women taking Veoza 45 mg, and 40% for women on placebo. The severity of hot flushes was also reduced in women taking Veoza, compared with women on placebo.

## What are the risks associated with Veoza?

For the full list of side effects and restrictions with Veoza, see the package leaflet.

The most common side effects with Veoza (which may affect up to 1 in 10 people) include diarrhoea and difficulty sleeping.

Veoza must not be used together with moderate or strong 'CYP1A2 inhibitor medicines' as these may reduce the breakdown of Veoza in the body and increase the risk of side effects; it must also not be used during pregnancy or if pregnancy is suspected.

## Why is Veoza authorised in the EU?

Veoza was shown to be effective at reducing the frequency and severity of hot flushes associated with menopause; the medicine is well-tolerated with an acceptable safety profile.

The European Medicines Agency therefore decided that Veoza's benefits are greater than its risks and it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Veoza?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Veoza have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Veoza are continuously monitored. Suspected side effects reported with Veoza are carefully evaluated and any necessary action taken to protect patients.

## Other information about Veoza

Veoza received a marketing authorisation valid throughout the EU on 7 December 2023.

Veoza : EPAR - Medicine overview

Reference Number: EMA/482166/2023

English (EN) (117.21 KB - PDF)

**First published:** 20/12/2023

[View](/en/documents/overview/veoza-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-703)

български (BG) (141.05 KB - PDF)

**First published:**

20/12/2023

[View](/bg/documents/overview/veoza-epar-medicine-overview_bg.pdf)

español (ES) (117.61 KB - PDF)

**First published:**

20/12/2023

[View](/es/documents/overview/veoza-epar-medicine-overview_es.pdf)

čeština (CS) (138.26 KB - PDF)

**First published:**

20/12/2023

[View](/cs/documents/overview/veoza-epar-medicine-overview_cs.pdf)

dansk (DA) (116.8 KB - PDF)

**First published:**

20/12/2023

[View](/da/documents/overview/veoza-epar-medicine-overview_da.pdf)

Deutsch (DE) (119.91 KB - PDF)

**First published:**

20/12/2023

[View](/de/documents/overview/veoza-epar-medicine-overview_de.pdf)

eesti keel (ET) (116.2 KB - PDF)

**First published:**

20/12/2023

[View](/et/documents/overview/veoza-epar-medicine-overview_et.pdf)

ελληνικά (EL) (149.02 KB - PDF)

**First published:**

20/12/2023

[View](/el/documents/overview/veoza-epar-medicine-overview_el.pdf)

français (FR) (118.68 KB - PDF)

**First published:**

20/12/2023

[View](/fr/documents/overview/veoza-epar-medicine-overview_fr.pdf)

hrvatski (HR) (136.57 KB - PDF)

**First published:**

20/12/2023

[View](/hr/documents/overview/veoza-epar-medicine-overview_hr.pdf)

italiano (IT) (117.01 KB - PDF)

**First published:**

20/12/2023

[View](/it/documents/overview/veoza-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (145.72 KB - PDF)

**First published:**

20/12/2023

[View](/lv/documents/overview/veoza-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (139.12 KB - PDF)

**First published:**

20/12/2023

[View](/lt/documents/overview/veoza-epar-medicine-overview_lt.pdf)

magyar (HU) (138.07 KB - PDF)

**First published:**

20/12/2023

[View](/hu/documents/overview/veoza-epar-medicine-overview_hu.pdf)

Malti (MT) (140.66 KB - PDF)

**First published:**

20/12/2023

[View](/mt/documents/overview/veoza-epar-medicine-overview_mt.pdf)

Nederlands (NL) (117.4 KB - PDF)

**First published:**

20/12/2023

[View](/nl/documents/overview/veoza-epar-medicine-overview_nl.pdf)

polski (PL) (139.26 KB - PDF)

**First published:**

20/12/2023

[View](/pl/documents/overview/veoza-epar-medicine-overview_pl.pdf)

português (PT) (118.54 KB - PDF)

**First published:**

20/12/2023

[View](/pt/documents/overview/veoza-epar-medicine-overview_pt.pdf)

română (RO) (136.5 KB - PDF)

**First published:**

20/12/2023

[View](/ro/documents/overview/veoza-epar-medicine-overview_ro.pdf)

slovenčina (SK) (138.11 KB - PDF)

**First published:**

20/12/2023

[View](/sk/documents/overview/veoza-epar-medicine-overview_sk.pdf)

slovenščina (SL) (136.57 KB - PDF)

**First published:**

20/12/2023

[View](/sl/documents/overview/veoza-epar-medicine-overview_sl.pdf)

Suomi (FI) (115.32 KB - PDF)

**First published:**

20/12/2023

[View](/fi/documents/overview/veoza-epar-medicine-overview_fi.pdf)

svenska (SV) (116.02 KB - PDF)

**First published:**

20/12/2023

[View](/sv/documents/overview/veoza-epar-medicine-overview_sv.pdf)

## Product information

Veoza : EPAR - Product information

English (EN) (2.11 MB - PDF)

**First published:** 20/12/2023

**Last updated:** 21/03/2025

[View](/en/documents/product-information/veoza-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-765)

български (BG) (2.19 MB - PDF)

**First published:**

20/12/2023

**Last updated:**

21/03/2025

[View](/bg/documents/product-information/veoza-epar-product-information_bg.pdf)

español (ES) (2.11 MB - PDF)

**First published:**

20/12/2023

**Last updated:**

21/03/2025

[View](/es/documents/product-information/veoza-epar-product-information_es.pdf)

čeština (CS) (2.18 MB - PDF)

**First published:**

20/12/2023

**Last updated:**

21/03/2025

[View](/cs/documents/product-information/veoza-epar-product-information_cs.pdf)

dansk (DA) (2.52 MB - PDF)

**First published:**

20/12/2023

**Last updated:**

21/03/2025

[View](/da/documents/product-information/veoza-epar-product-information_da.pdf)

Deutsch (DE) (2.13 MB - PDF)

**First published:**

20/12/2023

**Last updated:**

21/03/2025

[View](/de/documents/product-information/veoza-epar-product-information_de.pdf)

eesti keel (ET) (2.11 MB - PDF)

**First published:**

20/12/2023

**Last updated:**

21/03/2025

[View](/et/documents/product-information/veoza-epar-product-information_et.pdf)

ελληνικά (EL) (2.2 MB - PDF)

**First published:**

20/12/2023

**Last updated:**

21/03/2025

[View](/el/documents/product-information/veoza-epar-product-information_el.pdf)

français (FR) (2.18 MB - PDF)

**First published:**

20/12/2023

**Last updated:**

21/03/2025

[View](/fr/documents/product-information/veoza-epar-product-information_fr.pdf)

hrvatski (HR) (2.66 MB - PDF)

**First published:**

20/12/2023

**Last updated:**

21/03/2025

[View](/hr/documents/product-information/veoza-epar-product-information_hr.pdf)

íslenska (IS) (2.12 MB - PDF)

**First published:**

20/12/2023

**Last updated:**

21/03/2025

[View](/is/documents/product-information/veoza-epar-product-information_is.pdf)

italiano (IT) (2.12 MB - PDF)

**First published:**

20/12/2023

**Last updated:**

21/03/2025

[View](/it/documents/product-information/veoza-epar-product-information_it.pdf)

latviešu valoda (LV) (2.18 MB - PDF)

**First published:**

20/12/2023

**Last updated:**

21/03/2025

[View](/lv/documents/product-information/veoza-epar-product-information_lv.pdf)

lietuvių kalba (LT) (2.18 MB - PDF)

**First published:**

20/12/2023

**Last updated:**

21/03/2025

[View](/lt/documents/product-information/veoza-epar-product-information_lt.pdf)

magyar (HU) (322.3 KB - PDF)

**First published:**

20/12/2023

**Last updated:**

21/03/2025

[View](/hu/documents/product-information/veoza-epar-product-information_hu.pdf)

Malti (MT) (2.59 MB - PDF)

**First published:**

20/12/2023

**Last updated:**

21/03/2025

[View](/mt/documents/product-information/veoza-epar-product-information_mt.pdf)

Nederlands (NL) (2.12 MB - PDF)

**First published:**

20/12/2023

**Last updated:**

21/03/2025

[View](/nl/documents/product-information/veoza-epar-product-information_nl.pdf)

norsk (NO) (2.12 MB - PDF)

**First published:**

20/12/2023

**Last updated:**

21/03/2025

[View](/no/documents/product-information/veoza-epar-product-information_no.pdf)

polski (PL) (2.19 MB - PDF)

**First published:**

20/12/2023

**Last updated:**

21/03/2025

[View](/pl/documents/product-information/veoza-epar-product-information_pl.pdf)

português (PT) (2.13 MB - PDF)

**First published:**

20/12/2023

**Last updated:**

21/03/2025

[View](/pt/documents/product-information/veoza-epar-product-information_pt.pdf)

română (RO) (2.17 MB - PDF)

**First published:**

20/12/2023

**Last updated:**

21/03/2025

[View](/ro/documents/product-information/veoza-epar-product-information_ro.pdf)

slovenčina (SK) (2.19 MB - PDF)

**First published:**

20/12/2023

**Last updated:**

21/03/2025

[View](/sk/documents/product-information/veoza-epar-product-information_sk.pdf)

slovenščina (SL) (2.16 MB - PDF)

**First published:**

20/12/2023

**Last updated:**

21/03/2025

[View](/sl/documents/product-information/veoza-epar-product-information_sl.pdf)

Suomi (FI) (2.12 MB - PDF)

**First published:**

20/12/2023

**Last updated:**

21/03/2025

[View](/fi/documents/product-information/veoza-epar-product-information_fi.pdf)

svenska (SV) (2.12 MB - PDF)

**First published:**

20/12/2023

**Last updated:**

21/03/2025

[View](/sv/documents/product-information/veoza-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** VR/0000255226 21/03/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Veoza : EPAR - All authorised presentations

English (EN) (250.66 KB - PDF)

**First published:** 20/12/2023

**Last updated:** 19/02/2024

[View](/en/documents/all-authorised-presentations/veoza-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-177)

български (BG) (182.2 KB - PDF)

**First published:**

20/12/2023

**Last updated:**

19/02/2024

[View](/bg/documents/all-authorised-presentations/veoza-epar-all-authorised-presentations_bg.pdf)

español (ES) (251.59 KB - PDF)

**First published:**

20/12/2023

**Last updated:**

19/02/2024

[View](/es/documents/all-authorised-presentations/veoza-epar-all-authorised-presentations_es.pdf)

čeština (CS) (154.66 KB - PDF)

**First published:**

20/12/2023

**Last updated:**

19/02/2024

[View](/cs/documents/all-authorised-presentations/veoza-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (250.63 KB - PDF)

**First published:**

20/12/2023

**Last updated:**

19/02/2024

[View](/da/documents/all-authorised-presentations/veoza-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (251.14 KB - PDF)

**First published:**

20/12/2023

**Last updated:**

19/02/2024

[View](/de/documents/all-authorised-presentations/veoza-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (251.65 KB - PDF)

**First published:**

20/12/2023

**Last updated:**

19/02/2024

[View](/et/documents/all-authorised-presentations/veoza-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (296.27 KB - PDF)

**First published:**

20/12/2023

**Last updated:**

19/02/2024

[View](/el/documents/all-authorised-presentations/veoza-epar-all-authorised-presentations_el.pdf)

français (FR) (267.68 KB - PDF)

**First published:**

20/12/2023

**Last updated:**

19/02/2024

[View](/fr/documents/all-authorised-presentations/veoza-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (292.49 KB - PDF)

**First published:**

20/12/2023

**Last updated:**

19/02/2024

[View](/hr/documents/all-authorised-presentations/veoza-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (250.49 KB - PDF)

**First published:**

20/12/2023

**Last updated:**

19/02/2024

[View](/is/documents/all-authorised-presentations/veoza-epar-all-authorised-presentations_is.pdf)

italiano (IT) (251.33 KB - PDF)

**First published:**

20/12/2023

**Last updated:**

19/02/2024

[View](/it/documents/all-authorised-presentations/veoza-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (178.91 KB - PDF)

**First published:**

20/12/2023

**Last updated:**

19/02/2024

[View](/lv/documents/all-authorised-presentations/veoza-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (295.17 KB - PDF)

**First published:**

20/12/2023

**Last updated:**

19/02/2024

[View](/lt/documents/all-authorised-presentations/veoza-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (294.59 KB - PDF)

**First published:**

20/12/2023

**Last updated:**

19/02/2024

[View](/hu/documents/all-authorised-presentations/veoza-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (295.68 KB - PDF)

**First published:**

20/12/2023

**Last updated:**

19/02/2024

[View](/mt/documents/all-authorised-presentations/veoza-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (251.31 KB - PDF)

**First published:**

20/12/2023

**Last updated:**

19/02/2024

[View](/nl/documents/all-authorised-presentations/veoza-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (251.01 KB - PDF)

**First published:**

20/12/2023

**Last updated:**

19/02/2024

[View](/no/documents/all-authorised-presentations/veoza-epar-all-authorised-presentations_no.pdf)

polski (PL) (270.18 KB - PDF)

**First published:**

20/12/2023

**Last updated:**

19/02/2024

[View](/pl/documents/all-authorised-presentations/veoza-epar-all-authorised-presentations_pl.pdf)

português (PT) (251.28 KB - PDF)

**First published:**

20/12/2023

**Last updated:**

19/02/2024

[View](/pt/documents/all-authorised-presentations/veoza-epar-all-authorised-presentations_pt.pdf)

română (RO) (178.26 KB - PDF)

**First published:**

20/12/2023

**Last updated:**

19/02/2024

[View](/ro/documents/all-authorised-presentations/veoza-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (180.05 KB - PDF)

**First published:**

20/12/2023

**Last updated:**

19/02/2024

[View](/sk/documents/all-authorised-presentations/veoza-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (177.9 KB - PDF)

**First published:**

20/12/2023

**Last updated:**

19/02/2024

[View](/sl/documents/all-authorised-presentations/veoza-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (251.02 KB - PDF)

**First published:**

20/12/2023

**Last updated:**

19/02/2024

[View](/fi/documents/all-authorised-presentations/veoza-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (250.38 KB - PDF)

**First published:**

20/12/2023

**Last updated:**

19/02/2024

[View](/sv/documents/all-authorised-presentations/veoza-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Veoza Active substance fezolinetant International non-proprietary name (INN) or common name fezolinetant Therapeutic area (MeSH)

- Menopause
- Hot Flashes

Anatomical therapeutic chemical (ATC) code G02CX06

### Pharmacotherapeutic group

Other gynecologicals

### Therapeutic indication

Veoza is indicated for the treatment of moderate to severe vasomotor symptoms (VMS) associated with menopause.

## Authorisation details

EMA product number EMEA/H/C/005851

Additional monitoring

This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under [additional monitoring](/node/68821) .

Marketing authorisation holder

Astellas Pharma Europe B.V.

Sylviusweg 62

Opinion adopted 12/10/2023 Marketing authorisation issued 07/12/2023 Revision 4

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Veoza : EPAR - Procedural steps taken and scientific information after the authorisation

English (EN) (122.12 KB - PDF)

**First published:** 21/03/2025

[View](/en/documents/procedural-steps-after/veoza-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Veoza :  EPAR - Procedural steps taken and scientific information after the authorisation (archive)

English (EN) (146.4 KB - PDF)

**First published:** 19/02/2024

**Last updated:** 21/03/2025

[View](/en/documents/procedural-steps-after/veoza-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

Veoza : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation(s)

English (EN) (1.95 MB - PDF)

**First published:** 14/02/2025

[View](/en/documents/scientific-conclusion/veoza-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations_en.pdf)

## Initial marketing authorisation documents

Veoza : EPAR - Public assessment report

Adopted

English (EN) (7.29 MB - PDF)

**First published:** 20/12/2023

[View](/en/documents/assessment-report/veoza-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Veoza

Adopted

Reference Number: EMA/CHMP/440243/2023

English (EN) (133.26 KB - PDF)

**First published:** 13/10/2023

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-veoza_en.pdf)

#### News on Veoza

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 9-12 October 2023](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-9-12-october-2023) 13/10/2023

#### More information on Veoza

- [Veoza - direct healthcare professional communication (DHPC)](/en/medicines/dhpc/veoza)
- [Fezolinetant Experience for the Treatment of Vasomotor Symptoms Associated with Menopause Among Women in a German Real-life Setting - post-authorisation study](https://catalogues.ema.europa.eu/study/1000000132)

**This page was last updated on** 21/03/2025

## Share this page

[Back to top](#main-content)